143 related articles for article (PubMed ID: 29540229)
1. A comparison of nephrotoxicity between patients with a solitary-functioning kidney and those with bilateral-functioning kidneys in cisplatin-based chemotherapy for advanced urothelial carcinoma: a Japanese retrospective multi-institutional study.
Inoue T; Miyazaki J; Ichioka D; Narita S; Kageyama S; Sugimoto M; Mitsuzuka K; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Matsui Y; Fujie K; Habuchi T; Nishiyama H
BMC Cancer; 2018 Mar; 18(1):290. PubMed ID: 29540229
[TBL] [Abstract][Full Text] [Related]
2. Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients.
Ishitsuka R; Miyazaki J; Ichioka D; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Kawai K; Nishiyama H
Clin Exp Nephrol; 2017 Aug; 21(4):732-740. PubMed ID: 27565169
[TBL] [Abstract][Full Text] [Related]
3. Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract.
Cho KS; Joung JY; Seo HK; Cho IC; Chung HS; Chung J; Lee KH
Cancer Chemother Pharmacol; 2011 Apr; 67(4):769-74. PubMed ID: 20532510
[TBL] [Abstract][Full Text] [Related]
4. [Impact of different methods of estimating renal function on determining eligibility for cisplatin (CDDP)-based chemotherapy in patients with invasive urothelial carcinoma].
Goto T; Yoshimura K; Matsui Y; Shimizu Y; Inoue T; Okubo K; Kamba T; Nishiyama H; Ogawa O
Hinyokika Kiyo; 2011 Dec; 57(12):671-6. PubMed ID: 22240299
[TBL] [Abstract][Full Text] [Related]
5. The renal safety and efficacy of combined gemcitabine plus cisplatin and gemcitabine plus carboplatin chemotherapy in Chinese patients with a solitary kidney after nephroureterectomy.
Sun P; Xue C; Li LR; Shao C; An X; Thomas R; Yang W; Deng YF; Jiang WQ; Shi YX
Cancer Chemother Pharmacol; 2017 Jul; 80(1):37-44. PubMed ID: 28534209
[TBL] [Abstract][Full Text] [Related]
6. Are the Formulas Used to Estimate Renal Function Adequate for Patients Treated With Cisplatin-Based Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Carcinoma?
Niwa N; Kikuchi E; Masashi M; Tanaka N; Nishiyama T; Miyajima A; Saito S; Oya M
Clin Genitourin Cancer; 2016 Oct; 14(5):e501-e507. PubMed ID: 27236770
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study.
Nakagawa T; Komemushi Y; Kawai T; Otsuka M; Miyakawa J; Uemura Y; Kanatani A; Taguchi S; Naito A; Suzuki M; Nishimatsu H; Hirano Y; Tanaka Y; Matsumoto A; Miyazaki H; Fujimura T; Fukuhara H; Kume H; Igawa Y; Homma Y
World J Urol; 2017 Oct; 35(10):1569-1575. PubMed ID: 28397000
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome.
Yafi FA; Tanguay S; Rendon R; Jacobsen N; Fairey A; Izawa J; Kapoor A; Black P; Lacombe L; Chin J; So A; Lattouf JB; Bell D; Fradet Y; Saad F; Matsumoto E; Drachenberg D; Cagiannos I; Kassouf W
Urol Oncol; 2014 Jan; 32(1):31.e17-24. PubMed ID: 23428535
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of renal function using cystatin C-based estimated glomerular filtration rate in patients with urothelial carcinoma treated with gemcitabine and cisplatin chemotherapy.
Nishimura F; Ushijima T; Hamada S; Kadowaki D; Miyamura S; Oniki K; Saruwatari J
J Clin Pharm Ther; 2021 Dec; 46(6):1622-1628. PubMed ID: 34339546
[TBL] [Abstract][Full Text] [Related]
10. Early prediction of cisplatin-induced nephrotoxicity by urinary vanin-1 in patients with urothelial carcinoma.
Hosohata K; Washino S; Kubo T; Natsui S; Fujisaki A; Kurokawa S; Ando H; Fujimura A; Morita T
Toxicology; 2016 Jun; 359-360():71-5. PubMed ID: 27317936
[TBL] [Abstract][Full Text] [Related]
11. The impact of a solitary kidney on tolerability to gemcitabine plus cisplatin chemotherapy in urothelial carcinoma patients: a retrospective study.
Kondo M; Hotta Y; Ando R; Yasui T; Kimura K
Cancer Chemother Pharmacol; 2017 May; 79(5):995-1001. PubMed ID: 28391352
[TBL] [Abstract][Full Text] [Related]
12. New classification of hydronephrosis on 18F-FDG-PET/CT predicts post-operative renal function and muscle-invasive disease in patients with upper urinary tract urothelial carcinoma.
Asai S; Fukumoto T; Watanabe R; Koyama K; Sawada Y; Noda T; Miura N; Yanagihara Y; Miyauchi Y; Miyagawa M; Kikugawa T; Saika T
Jpn J Clin Oncol; 2018 Nov; 48(11):1022-1027. PubMed ID: 30252103
[TBL] [Abstract][Full Text] [Related]
13. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy.
Xylinas E; Rink M; Margulis V; Clozel T; Lee RK; Comploj E; Novara G; Raman JD; Lotan Y; Weizer A; Roupret M; Pycha A; Scherr DS; Seitz C; Ficarra V; Trinh QD; Karakiewicz PI; Montorsi F; Zerbib M; Shariat SF;
BJU Int; 2013 Aug; 112(4):453-61. PubMed ID: 23464979
[TBL] [Abstract][Full Text] [Related]
14. Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
Hinai Y; Motoyama S; Niioka T; Miura M
J Clin Pharm Ther; 2013 Dec; 38(6):498-503. PubMed ID: 24102360
[TBL] [Abstract][Full Text] [Related]
15. Prediction of renal function after nephroureterectomy in patients with upper tract urothelial carcinoma.
Hashimoto T; Ohno Y; Nakashima J; Gondo T; Nakagami Y; Namiki K; Horiguchi Y; Yoshioka K; Ohori M; Tachibana M
Jpn J Clin Oncol; 2015 Nov; 45(11):1064-8. PubMed ID: 26355160
[TBL] [Abstract][Full Text] [Related]
16. Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma.
Kaag M; Trost L; Thompson RH; Favaretto R; Elliott V; Shariat SF; Maschino A; Vertosick E; Raman JD; Dalbagni G
BJU Int; 2014 Nov; 114(5):674-9. PubMed ID: 24314050
[TBL] [Abstract][Full Text] [Related]
17. Correlation of prechemotherapy urinary megalin ectodomain (A-megalin) levels with the development of cisplatin-induced nephrotoxicity: a prospective observational study.
Shoji S; Hosojima M; Kabasawa H; Kondo R; Miura S; Watanabe S; Aoki N; Kaseda R; Kuwahara S; Tanabe N; Hirayama Y; Narita I; Kikuchi T; Kagamu H; Saito A
BMC Cancer; 2019 Dec; 19(1):1170. PubMed ID: 31791266
[TBL] [Abstract][Full Text] [Related]
18. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy.
Kaag MG; O'Malley RL; O'Malley P; Godoy G; Chen M; Smaldone MC; Hrebinko RL; Raman JD; Bochner B; Dalbagni G; Stifelman MD; Taneja SS; Huang WC
Eur Urol; 2010 Oct; 58(4):581-7. PubMed ID: 20619530
[TBL] [Abstract][Full Text] [Related]
19. Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy.
Shao IH; Lin YH; Hou CP; Juang HH; Chen CL; Chang PL; Tsui KH
Drug Des Devel Ther; 2014; 8():1985-90. PubMed ID: 25364228
[TBL] [Abstract][Full Text] [Related]
20. Investigation of estimated glomerular filtration rate and its perioperative change in patients with upper urinary tract urothelial carcinoma: A multi-institutional retrospective study.
Koguchi D; Matsumoto K; Ikeda M; Taoka Y; Hirayama T; Murakami Y; Utsunomiya T; Matsuda D; Okuno N; Irie A; Iwamura M
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e420-e427. PubMed ID: 29436164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
